O33 Longitudinal assessment of biomarkers in NOBILITY, a randomized, phase II clinical trial of obinutuzumab for treatment of proliferative lupus nephritis

• Richard A Furie,
• Sander W Tas,
• Edward M Vital,
• Ana Malvar,
• Thomas Schindler,
• Harini Raghu,
• Cary M Looney,
• Jorge A Ross Terres,
• Veronica G Anania,
• Ashley Mao,
• Elsa Martins

Affiliations

Richard A Furie

Division of Rheumatology, Northwell Health, Great Neck, New York City, New York, USA

Sander W Tas

Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centres, Amsterdam, The Netherlands

Edward M Vital

7Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

Ana Malvar

1Nephrology, Hospital Fernandez, Argentina

Thomas Schindler

8 F. Hoffmann-La Roche AG, Basel, Switzerland

Harini Raghu

2VA Palo Alto Health Care System, Palo Alto, California, USA

Cary M Looney

3 Genentech Inc, South San Francisco, California, USA

Jorge A Ross Terres

Eli Lilly and Company, Indianapolis, Indiana, USA

Veronica G Anania

5Genentech, Inc., South San Francisco, CA, USA

Ashley Mao

6Hoffmann-La Roche Ltd, Mississauga, ON, Canada

Elsa Martins

4F. Hoffmann-La Roche Ltd, Basel, Switzerland